ReviewIbrain2026
Beyond motor recovery: Stem cell-derived exosomes for sensory restoration and neuropathic pain relief after spinal cord injury.
Review in Ibrain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) causes persistent neurological deficits that extend beyond motor impairment, with sensory dysfunction and neuropathic pain substantially compromising quality of life. Stem cell-derived exosomes have emerged as promising cell-free therapeutic agents because they deliver diverse bioactive molecules, including proteins, microRNAs, and long non-coding RNAs, while retaining many of the paracrine benefits of stem cells. This review summarizes recent advances in the application of stem cell-derived exosomes for sensory restoration and neuropathic pain relief after SCI, with particular emphasis on their underlying mechanisms and emerging delivery strategies. We first discuss exosome biogenesis, molecular composition, intercellular communication, and engineering approaches. We then summarize their established roles in motor recovery through neuroprotection, immunomodulation, axonal regeneration and myelin repair. Importantly, we highlight emerging evidence that stem cell-derived exosomes may restore sensory function by promoting axonal regeneration, synaptic remodeling, neural differentiation, and glial metabolic reprogramming. In parallel, exosomes alleviate neuropathic pain by suppressing microglial and astrocytic activation, modulating TLR/MyD88/NF-κB signaling, reducing neuroinflammation and pathological nociceptive signaling, and promoting remyelination and tissue repair. Exosomes also preserve blood-spinal cord barrier integrity through regulation of endothelial cells, pericytes, matrix metalloproteinases, and vascular signaling, for both motor and sensory recovery. Finally, we discuss challenges related to exosome heterogeneity, manufacturing standardization, delivery, safety, and limited sensory-specific evidence, and highlight engineering and biomaterial-based strategies for future clinical translation. Overall, stem cell-derived exosomes represent a multifunctional therapeutic platform with potential to move SCI treatment beyond motor recovery toward comprehensive sensory restoration and pain management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.